SCHEMBL20705291

SCHEMBL20705291

CC(C)(C)OC(=O)N1CC(N=[N+]=[N-])CC1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 2/20 0.51
▸ ANPEP P15144 2/20 0.51
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ DPP4 P27487 4/20 0.35
▸ DPP8 Q6V1X1 4/20 0.35
▸ DPP9 Q86TI2 4/20 0.35
▸ DPP7 Q9UHL4 4/20 0.35
▸ NR1H2 P55055 1/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HTRA1 Q92743 1/20 0.33
▸ ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13836866 1.00 MMP2 (0.51) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL23038367 1.00 MMP2 (0.51) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL17859969 1.00 MMP2 (0.51) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL29071685 1.00 MMP2 (0.51) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL25594426 0.88 MMP2 (0.41) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL20789374 0.88 MMP2 (0.41) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL30476454 0.88 MMP2 (0.50) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL30685061 0.88 MMP2 (0.50) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL25257322 0.88 MMP2 (0.41) MMP2ANPEPHSD17B10CYP1A2POLB
SCHEMBL13494285 0.87 MMP2 (0.70) MMP2ANPEPCYP1A2POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117180290-A Arginase inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2023-12-08 — — CN disclosed
CN-117186134-A Arginase inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2023-12-08 — — CN disclosed
US-20230365599-A1 Arginase Inhibitors and Methods of Use Thereof ASTRAZENECA AB (SE) 2023-11-16 — — US disclosed
CN-111712302-B Arginase inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2023-09-19 — — CN disclosed
EP-3661922-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF Dyax Corp. (US) 2020-06-10 — — EP disclosed
WO-2019028362-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF DYAX CORP. (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365599-A1 Arginase Inhibitors and Methods of Use Thereof ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MMP2 999/4885ANPEP 1703/4885HSD17B10 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback